Knowing Nader as well as I do after hanging on his every word for almost 2 years...if the results were a slam dunk he would have been shouting it from the rooftops. That's the logical conclusion and it's why the stock tanked today.
Nader has not been known to show restraint when given the chance to hype the company, and the CD12 topline results would be the ultimate opportunity to do so.
Now maybe the results are great and there is a reason for the delay. Maybe Dr Rahman has restrained Nader somehow or perhaps there's a legitimate reason instigated by the FDA. I really hope that's the case but my guess is that the 28 day primary endpoint results weren't enough to easily convince the FDA so we move on to 42 days and the trial is still considered active, so no definitive material finding has been made and thus there is no need to report the results yet. Just my guess.